Skip to main content

sipuleucel-T

Generic: sipuleucel-T·Brand: Provenge

sipuleucel-T: 2 clinical trials tracked.

sipuleucel-T evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sipuleucel-T, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

NCT07756593Registry updated 2026-08-10·Phase 1
Not yet recruiting

Primary endpoint: Frequency of dose-limiting toxicities (Cohort 1 only)

Interventionalopen30 targetStarted 2026-11Completion 2031-011 site · United StatesWashington University School of Medicine

A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog

NCT05751941Registry updated 2025-12-15·Phase 2
Recruiting

Primary endpoint: Cumulative APC Activation

InterventionalRandomizedopen26 targetStarted 2023-02Completion 2026-121 site · United StatesH. Lee Moffitt Cancer Center and Research Institute